• 1
    Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 1989; 320: 14201421. Epub 1989/05/25.
  • 2
    Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185: 14131422. Epub 1997/04/21.
  • 3
    Rinnooy Kan EA, Wright SD, Welte K, Wang CY. Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol 1986; 98: 181187. Epub 1986/03/01.
  • 4
    Alegre ML, Tso JY, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155: 15441555. Epub 1995/08/01.
  • 5
    Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 25982608. Epub 2005/06/24.
  • 6
    Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614623. Epub 2010/03/13.
  • 7
    Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 29472954. Epub 1997/03/15.
  • 8
    Chatenoud L. Diabetes: Type 1 diabetes mellitus—A door opening to a real therapy? Nat Rev Endocrinol 2011; 7: 564566. Epub 2011/09/01.
  • 9
    Yu XZ, Nitta Y, Bidwell SJ, Anasetti C. Additive effects of anti-CD3 and anti-CD28 prolongation of allogeneic skin graft survival. Transplantation 2001; 72: 1862. Epub 2001/12/12.
  • 10
    Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 16. Epub 1997/01/15.
  • 11
    You S, Chatenoud L. New generation CD3 monoclonal antibodies: Are we ready to have them back in clinical transplantation? Curr Opin Org Transplant 2010; 15: 720724. Epub 2010/10/01.
  • 12
    Kohm AP, Williams JS, Bickford AL, et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 2005; 174: 45254534. Epub 2005/04/09.
  • 13
    You S, Zuber J, Kuhn C, et al. Induction of allograft tolerance by monoclonal CD3 antibodies: A matter of timing. Am J Transplant 2012; 12: 29092919.
  • 14
    Jones ND, Van Maurik A, Hara M, Gilot BJ, Morris PJ, Wood KJ. T-cell activation, proliferation, and memory after cardiac transplantation in vivo. Ann Surg 1999; 229: 570578.
  • 15
    Armstrong AT, Strauch AR, Starling RC, Sedmak DD, Orosz CG. Morphometric analysis of neointimal formation in murine cardiac grafts: III. Dissociation of interstitial fibrosis from neointimal formation. Transplantation 1997; 64: 11981202.
  • 16
    Warnecke G, Feng G, Goto R, et al. CD4+ regulatory t cells generated in vitro with IFN-γ and allogeneic APC inhibit transplant arteriosclerosis. Am J Pathol 2010; 177: 464472.
  • 17
    Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo—Expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90: 13211327. doi: 10.097/TP.0b013e3181ff8772
  • 18
    Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140: 37663772.
  • 19
    Alegre ML, Collins AM, Pulito VL, et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody. J Immunol 1992; 148: 34613468.
  • 20
    Cole MS, Stellrecht KE, Shi JD, et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999; 68: 563571.
  • 21
    Carvalho-Gaspar M, Billing JS, Spriewald BM, Wood KJ. Chemokine gene expression during allograft rejection: Comparison of two quantitative PCR techniques. J Immunol Methods 2005; 301: 4152.
  • 22
    Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011; 187: 20152022.
  • 23
    Valle A, Jofra T, Stabilini A, Atkinson M, Roncarolo M-G, Battaglia M. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 2009; 58: 875881.
  • 24
    Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809813.
  • 25
    Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417430.
  • 26
    Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434438.
  • 27
    Wang CY, Mazer SP, Minamoto K, et al. Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation 2002; 105: 16091614.
  • 28
    Calne R. WOFIE hypothesis: Some thoughts on an approach toward allograft tolerance. Transplant Proc 1996; 28: 1152.
  • 29
    Jonker M, Slingerland W, Ossevoort M, et al. Induction of kidney graft acceptance by creating a window of opportunity for immunologic engagement (WOFIE) in rhesus monkeys. Transplant Proc 1998; 30: 24412443.
  • 30
    Calne RY, Watson CJE, Brons IGM, et al. Tolerance of porcine renal allografts induced by donor spleen cells and seven days' treatment with cyclosporine. Transplantation 1994; 57: 14331435.
  • 31
    Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 12981302.
  • 32
    Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199210.
  • 33
    Tseng S-Y, Waite JC, Liu M, Vardhana S, Dustin ML. T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C-θ. J Immunol 2008; 181: 48524863.
  • 34
    Wood KJ, Goto R. Mechanisms of rejection: Current perspectives. Transplantation 2012; 93: 110. doi: 1097/TP.0b013e31823cab44
  • 35
    Sayegh MH, Zheng X-G, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in Ctla4ig-treated murine cardiac allograft recipients. Transplantation 1997; 64: 16461650.
  • 36
    You S, Zuber J, Kuhn C, et al. Induction of allograft tolerance by monoclonal CD3 antibodies: A matter of timing. Am J Transplant 2012; 12: 29092919. Epub 2012/08/14.
  • 37
    Kendal AR, Chen Y, Regateiro FS, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208: 20432053.
  • 38
    Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature 2011; 480: 538542.
  • 39
    Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899911.
  • 40
    Chatenoud L, Bluestone JA. CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622632.